Xu, Xinyi
Guo, Ying
Gao, Wei
Huang, Meirong
Liu, Tingliang
Article History
Received: 22 September 2022
Revised: 16 February 2023
Accepted: 16 February 2023
First Online: 4 March 2023
Declarations
:
: The study protocol was approved by the Institutional Ethics Committee of Shanghai Children’s Medical Center (SCMCIRB-K2021058-1).
: Before ivabradine therapy was initiated, the off-label use and potential side effects were explained in detail to the parents, and informed written consent was obtained from the guardians of each patient.
: The authors declare that they have no conflicts of interest related.